Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
LACK OF INTERACTION BETWEEN PIZOTIFEN AND THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN IN HEALTHY-VOLUNTEERS
Autore:
SEABER EJ; GILLOTIN C; MOHANLAL R; LAYTON G; POSNER J; PECK R;
Indirizzi:
GLAXO WELLCOME RES & DEV LTD,GREENFORD RD GREENFORD UB6 0HE MIDDX ENGLAND
Titolo Testata:
Clinical drug investigation
fascicolo: 3, volume: 14, anno: 1997,
pagine: 221 - 225
SICI:
1173-2563(1997)14:3<221:LOIBPA>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
MIGRAINE; 311C90;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
13
Recensione:
Indirizzi per estratti:
Citazione:
E.J. Seaber et al., "LACK OF INTERACTION BETWEEN PIZOTIFEN AND THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN IN HEALTHY-VOLUNTEERS", Clinical drug investigation, 14(3), 1997, pp. 221-225

Abstract

This double-blind, randomised, two-period crossover study investigated the effect of pizotifen on the pharmacokinetics and tolerability profile of zolmitriptan (formerly 311C90), a novel selective 5-HT1D receptor agonist for acute migraine therapy. 13 healthy volunteers (mean age 31 years, range 19 to 41 years; mean weight 75 kg, range 62 to 89 kg) received oral pizotifen 1.5 mg or placebo once daily for 8 days witha washout period of at least 2 weeks between study periods. Oral zolmitriptan 10 mg was administered with the final dose of pizotifen or placebo. Pizotifen did not significantly affect the pharmacokinetic parameters of zolmitriptan, although in 4 subjects the time to peak plasmazolmitriptan concentration (t(max)) was increased in the presence of pizotifen (median increase 1.4 hours). Zolmitriptan caused a small, transient, clinically insignificant increase in blood pressure, which was not affected by pizotifen. No clinically relevant changes in heart rate or 12-lead ECGs were observed. One volunteer was withdrawn becauseof a brief, 5-beat run, asymptomatic episode of ventricular tachycardia 170 minutes after administration with zolmitriptan plus placebo; this was not considered related to the treatment. Zolmitriptan was well tolerated both alone and in combination with pizotifen. Thus, there isno contraindication to the use of zolmitriptan nor a need for dosage modification in patients concomitantly receiving pizotifen.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 00:47:37